Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib

Published:2017-03 Issue:3 Volume:12 Page:567-572
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Ho Chao-Chi,Liao Wei-Yu,Lin Chih-An,Shih Jin-Yuan,Yu Chong-Jen,Chih-Hsin Yang James

Funder

AstraZeneca

National Taiwan University Hospital

Ministry of Science and Technology Taiwan

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: status in 2016;Tan;J Thorac Oncol,2016

2. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer;Jänne;N Engl J Med,2015

3. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M;Thress;Nat Med,2015

4. Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor;Kim;J Thorac Oncol,2015

5. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients;Planchard;Ann Oncol,2015

Cited by 184 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A real world analysis of secondary BRAF variations after targeted therapy resistance in driver gene positive NSCLC;Scientific Reports;2024-09-01

2. Case report: Durable response of ensartinib targeting EML4-ALK fusion in osimertinib-resistant non-small cell lung cancer;Frontiers in Pharmacology;2024-07-29

3. Microwave-assisted synthesis of 2,5-dioxo-pyrano[3,2-c]quinoline-3-carboxylates and their investigation as antiproliferative agents targeting EGFR and/or BRAFV600E;Chemical Papers;2024-07-29

4. TP53 gain-of-function mutations promote osimertinib resistance via TNF-α–NF-κB signaling in EGFR-mutated lung cancer;npj Precision Oncology;2024-03-02

5. Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression;Translational Oncology;2024-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3